

## Ikonisys: new production record for Hospitex International

Paris, France, January 2, 2024 - 7:30 am CET - Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces that Hospitex International, world leader in thin layer cytology and cancer diagnostics, has achieved a new production record in its Sesto Fiorentino plant.

Hospitex received a sudden and urgent order for the production of 24,000 vials of CYTOfast Biobank - Hospitex's universal vial for the collection of biological samples -, which is compatible with cytology, FISH diagnostics and molecular biology. This important result enabled the customer to participate in a major international HPV screening program.

This performance suggests that Hospitex's production potential is above 500,000 units on a monthly basis in two shifts, without taking into account additional potential efficiency benefits through automation investments.

**Alessandro Nosei, Chief Operating Officer of Hospitex** states: *"I would like to thank all the collaborators of Hospitex for their hard work and professionalism. This is an excellent result which demonstrates that our constant pursuit of efficiency yields positive outcomes".*

### About Hospitex International

Hospitex International is the world leading company for cytology standardized monolayer preparations. With CYTOfast it has re-invented the cytological diagnostics. Hospitex offers a full range of integrated solutions aimed at streamlining diagnostic processes in cytology. The global shortage of expertise in pathology requires tools and technologies that enable diagnostic safety, efficiency and capacity building. In this area, Hospitex is recognized as the precision diagnostics player in cytology.

For more information: <https://www.hospitex.com/en/>

### Contact

#### Hospitex International

Marco Testini  
Investor Relations  
[marketing@hospitex.com](mailto:marketing@hospitex.com)

### About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® and Ikoniscope20max® platforms, fully-automated solutions designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to [www.ikonisys.com](http://www.ikonisys.com)

## Contacts

---

### **Ikonisys**

Alessandro Mauri  
CFO  
[investors@ikonisys.com](mailto:investors@ikonisys.com)

### **NewCap**

Louis-Victor Delouvrier/Aurélie Manavarere  
Investor Relations  
[Ikonisys@newcap.eu](mailto:Ikonisys@newcap.eu)  
Tel.: +33 (0)1 44 71 94 94

### **NewCap**

Nicolas Merigeau  
Media Relations  
[Ikonisys@newcap.eu](mailto:Ikonisys@newcap.eu)  
Tel.: +33 (0)1 44 71 94 98

## Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.